Skip to content
Open access

Intrathecal mesenchymal stem cell therapy in progressive multiple sclerosis: integrated blood and CSF profiling in the SMART-MS randomized trial

Sep 2026 · Fluids and Barriers of the CNS · 0 citations

TL;DR

It is suggested that intrathecal MSC exposure in progressive MS is associated with compartmentalized CSF proteomic changes rather than broad systemic immune alterations, demonstrating the value of integrated blood–CSF profiling for dissecting treatment-associated biology in CNS-targeted interventional trials.

Abstract

Therapeutic options for progressive multiple sclerosis (MS) remain limited, and the mechanisms engaged by intrathecal mesenchymal stem cell (MSC) therapy are incompletely understood. MSCs are proposed to exert immunomodulatory and trophic effects, yet most studies rely on targeted biomarkers and lack systems-level analysis across immune compartments. Here, we applied an integrated blood–cerebrospinal fluid (CSF) multi-omics framework to characterize responses after intrathecal MSC exposure in patients with progressive MS enrolled in the SMART-MS trial, a randomized, placebo-controlled crossover study of a single intrathecal MSC injection. Although the trial did not demonstrate a neuro-regenerative signal for the primary endpoint, exploratory MRI findings and adverse events, including fever and back pain, suggested localized responses after intrathecal administration. Within the 18-participant SMART-MS cohort, peripheral blood mass cytometry was analysed longitudinally across baseline, six months, and 12 months, whereas matched CSF proteomics was analysed using paired baseline and six-month samples from the first treatment period. Immune phenotypes and marker-derived functional program scores were quantified using mixed-effects modelling. To summarize CSF proteomic changes, we generated exploratory composite scores reflecting extracellular matrix/interface-associated, innate/vascular inflammatory, metabolic/cytoskeletal, and reactivity-associated proteins. These scores enabled exploratory integration with circulating immune programs. MSC exposure was not associated with broad remodelling of peripheral immune-cell composition or marker-derived functional programs across circulating lymphocyte, monocyte, B-cell, and NK-cell populations. Instead, the most consistent treatment-associated changes were observed within the CSF proteome, where MSC exposure was associated with coordinated extracellular-matrix-associated protein changes, including fibrillar collagens and matrix-regulatory proteins, together with changes in innate, vascular, metabolic, and cytoskeletal pathways. Inflammatory, metabolic, and reactivity-associated CSF protein signatures tended to show greater changes in exploratory analyses of patients with adverse events or spinal MRI reactivity, consistent with heterogeneous local responsiveness rather than a uniform response. Cross-compartment analyses showed weak and heterogeneous coupling between circulating immune programs and CSF proteomic changes. Together, these findings suggest that intrathecal MSC exposure in progressive MS is associated with compartmentalized CSF proteomic changes rather than broad systemic immune alterations. This study demonstrates the value of integrated blood–CSF profiling for dissecting treatment-associated biology in CNS-targeted interventional trials.

Read PDF

Similar papers

Open access Sep 2026

Effect of intrathecal injection of mesenchymal stem cell-neural progenitors on cerebrospinal fluid biomarkers in progressive multiple sclerosis

Abstract Mesenchymal stem cell-neural progenitors (MSC-NP) are a bone marrow mesenchymal stem cell–derived population of cells with trophic and immunomodulatory properties with therapeutic potential in multiple sclerosis (MS). Early phase clinical trials have investigated the safety and efficacy of intrathecal administ...

Violaine K. Harris, Andrea Jiang, S. Ricciarini et al. · 0 citations
Open access Sep 2026

Effect of mesenchymal stem cells on peripheral immune cells in multiple sclerosis: results from an international phase 2 clinical trial.

INTRODUCTION The MESEMS trial was a randomized, double-blind, Placebo (Pbo)-controlled, crossover phase 2 study evaluating the safety and efficacy of autologous mesenchymal stromal cells (MSC) in multiple sclerosis (MS). Although the trial did not demonstrate a significant effect on MRI disease activity, MSC may exert...

I. Schiavetti, Mark S. Freedman, S. Thebault et al. · 0 citations
Review Open access Sep 2026

Stem Cell-Based Therapies for Central Nervous System Demyelinating Diseases: Clinical Evidence, Therapeutic Niches, and Translational Boundaries

Central nervous system demyelinating disorders differ substantially in pathobiology, reversibility, and capacity for tissue repair. Disease-modifying therapies can suppress inflammatory activity in multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), but they do not replace lost oligodendrocytes...

Qian-Ping Luo, Dong-Gan Jin, Zhen-Ying Zhan · 0 citations
Review Open access Sep 2026

MULTIPLE SCLEROSIS: NEW IMMUNOMODULATORY STRATEGIES AND BIOMARKERS

Introduction and purpose: Multiple Sclerosis (MS) disability accumulation is driven primarily by compartmentalized, subclinical neuroinflammation and diffuse neurodegeneration, termed smouldering MS. While traditional disease-modifying therapies (DMTs) control peripheral relapses and focal MRI activity, halting this pr...

Natalia Kitala, Justyna Karliczek, K. Nycz et al. · 0 citations
Open access Oct 2026

Mesenchymal Stromal Cells Fuel Immunometabolic Reprogramming of Type 2 Conventional Dendritic Cells to Alleviate Systemic Sclerosis.

OBJECTIVE To investigate the clinical efficacy and underlying mechanisms of mesenchymal stromal cell (MSC) therapy in systemic sclerosis (SSc). METHODS We prospectively evaluated the efficacy of MSC therapy in SSc patients. To elucidate the therapeutic mechanisms, we integrated paired multi-omics data: proteomics (n=...

Zhi-Kang Wang, Sha Liu, Xin-Ping Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.